首页> 外文期刊>World Journal of Gastroenterology >Antibiotics and probiotics in treatment of inflammatory bowel disease.
【24h】

Antibiotics and probiotics in treatment of inflammatory bowel disease.

机译:抗生素和益生菌治疗炎症性肠病。

获取原文
获取原文并翻译 | 示例
           

摘要

Many experimental and clinical observations suggest that intestinal microflora plays a potential role in the pathogenesis of inflammatory bowel disease (IBD). Manipulation of the luminal content using antibiotics or probiotics represents a potentially effective therapeutic option. The available studies do not support the use of antibiotics in ulcerative colitis (UC). Antibiotics are effective in treating septic complications of Crohn's disease (CD) but their use as a primary therapy is more controversial, although this approach is frequently and successfully adopted in clinical practice. There is evidence that probiotic therapy may be effective in the prevention and treatment of mild to moderate UC. In contrast, a lack of successful study data at present precludes the widespread use of probiotics in the treatment of CD. Both antibiotics and probiotics appear to play a beneficial role in the treatment and prevention of pouchitis and further trials are warranted to fully quantify their clinical efficacy.
机译:许多实验和临床观察表明,肠道菌群在炎症性肠病(IBD)的发病机理中起着潜在的作用。使用抗生素或益生菌操纵内腔含量代表了潜在的有效治疗选择。现有的研究不支持在溃疡性结肠炎(UC)中使用抗生素。抗生素可有效治疗克罗恩氏病(CD)的败血症并发症,但其作为主要疗法的争议更大,尽管这种方法在临床实践中经常且成功地采用。有证据表明,益生菌疗法可能有效预防和治疗轻度至中度UC。相反,目前缺乏成功的研究数据排除了益生菌在CD治疗中的广泛应用。抗生素和益生菌似乎都在治疗和预防眼袋炎中发挥有益作用,因此有必要进行进一步的试验以充分量化其临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号